Addex Therapeutics Q1 EPS $(1.37) Up From $(5.20) YoY, Sales $268.83K Down From $542.43K YoY
Portfolio Pulse from Benzinga Newsdesk
Addex Therapeutics (NASDAQ:ADXN) reported Q1 EPS of $(1.37), a significant improvement from $(5.20) YoY. However, sales decreased by 50.44% to $268.83K from $542.43K YoY.
June 06, 2024 | 5:12 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Addex Therapeutics reported a significant improvement in EPS, reducing losses from $(5.20) to $(1.37) YoY. However, sales dropped by 50.44% to $268.83K.
The improvement in EPS is a positive sign, indicating better cost management or other efficiencies. However, the significant drop in sales is concerning and could offset the positive sentiment from the EPS improvement.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100